Inventor · disambiguated record
Klaus Pfizenmaier
Also filed as: PFIZENMAIER KLAUS
21 granted patents·5 pending applications·108 citations·filing 1991–2024
93Inventor score
Files withUNIV STUTTGART8PFIZENMAIER KLAUS6ONCOMATRYX BIOPHARMA S L3BIONTECH RNA PHARMACEUTICALS GMBH2BALIOPHARM AG1
Top patents by PatentIndex Score
26 records- 0195US12065472B2Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivityUNIV STUTTGART·Filed 2021·Granted Aug 20, 2024·3 cites·21 claims
- 0293US12173046B2TNFR2 agonists with improved stabilityUNIV STUTTGART·Filed 2024·Granted Dec 24, 2024·1 cites·7 claims
- 0390US11142558B2Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivityUNIV STUTTGART·Filed 2018·Granted Oct 12, 2021·5 cites·19 claims
- 0486US8859739B2Anti-huTNFR1 antibody and methods of use thereof for treatmentKONTERMANN ROLAND·Filed 2011·Granted Oct 14, 2014·19 cites·16 claims
- 0584US7368295B2Nanoparticles comprising biologically active TNF which is immobilized on the sameFRAUNHOFER GES FORSCHUNG·Filed 2002·Granted May 6, 2008·30 cites·67 claims
- 0679US10301368B2Cytokine fusion proteinsBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted May 28, 2019·4 cites·22 claims
- 0777US10137202B2Antibody-drug conjugates and immunotoxinsONCOMATRYX BIOPHARMA S L·Filed 2015·Granted Nov 27, 2018·4 cites·33 claims
- 0876US8927205B2Recombinant polypeptides of the members of the TNF ligand family and use thereofPFIZENMAIER KLAUS·Filed 2005·Granted Jan 6, 2015·6 cites·23 claims
- 0973US10570206B2Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereofUNIV STUTTGART·Filed 2017·Granted Feb 25, 2020·1 cites·18 claims
- 1069US10428149B2Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereofUNIV STUTTGART·Filed 2016·Granted Oct 1, 2019·1 cites·23 claims
- 1169US9045535B2huTNFR1 selective antagonistsUNIV STUTTGART·Filed 2013·Granted Jun 2, 2015·2 cites·4 claims
- 1269US5736138AMonoclonal antibodies with specific binding against membrane proteins on human cells, and pharmaceutical compositions containing themPFIZENMAIER KLAUS·Filed 1991·Granted Apr 7, 1998·31 cites·6 claims
- 1359US2022267410A1TNFR2 Agonists with Improved StabilityUNIV STUTTGART·Filed 2020·Application pending·0 cites
- 1458US8980265B2Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines)PFIZENMAIER KLAUS·Filed 2003·Granted Mar 17, 2015·1 cites·3 claims
- 1556US9944708B2Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines)BIONTECH AG·Filed 2014·Granted Apr 17, 2018·0 cites·5 claims
- 1655US8404238B2huTNFR1 selective antagonistsPFIZENMAIER KLAUS·Filed 2008·Granted Mar 26, 2013·0 cites·9 claims
- 1753US10864278B2Antibody-drug conjugates and immunotoxinsONCOMATRYX BIOPHARMA S L·Filed 2018·Granted Dec 15, 2020·0 cites·17 claims
- 1852US10808019B2Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligandsBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2019·Granted Oct 20, 2020·0 cites·21 claims
- 1951US9822179B2Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereforPFIZENMAIER KLAUS·Filed 2012·Granted Nov 21, 2017·0 cites·17 claims
- 2050US2004126791A1Compositions and methods for treating trail-resistant cancer cellsRIBOPHARMA AG·Filed 2003·Application pending·0 cites
- 2143US2002099180A1Human FAP-alpha-specific antibodiesFiled 2001·Application pending·0 cites
- 2242US11028178B2Method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibodyBALIOPHARM AG·Filed 2018·Granted Jun 8, 2021·0 cites·16 claims
- 2341US10689452B2Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereofUNIV STUTTGART·Filed 2017·Granted Jun 23, 2020·0 cites·24 claims
- 2439US2005244370A1Selective local activation of members of the TNF receptor family by systemically inactive non-antibody TNF ligand fusion proteinsPFIZENMAIER KLAUS·Filed 2005·Application pending·0 cites
- 2532US2004053829A1Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrugFiled 2001·Application pending·0 cites
- 2628US10004812B2Antibody-drug conjugates and immunotoxinsONCOMATRYX BIOPHARMA S L·Filed 2015·Granted Jun 26, 2018·0 cites·22 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →